PCN32 ECONOMIC EVALUATION OF SUNITINIB, SORAFENIB, BEVACIZUMAB/ INTERFERON ALPHA AND TEMSIROLIMUS IN FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ISRAEL
Greenberg D g Ben-Gurion University of the Negev, Beer-Sheva, Israel OBJECTIVES: Metastatic renal cell carcinoma (mRCC) is highly resistant to chemotherapeutics, rendering limited anti-tumor effect. New treatments such as Sunitinib, Sorafenib, Bevacizumab/Interferon-alpha (INF-alpha), and Temsirolimus have been recently licensed for fi rst-line treatment of patients with mRCC. We assessed the costeffectiveness of these therapies from the perspective of the Israeli health care payer.
METHODS:
We used a Markov model with a 10-year time horizon to simulate disease progression, survival, and cost outcomes for a hypothetical cohort of mRCC patients. Although no head-to-head trials comparing the new treatment modalities are available, most studies had compared the new therapies against INF-alpha, thus allowing an indirect comparison of clinical effi cacy. Utility weights were estimated from Sunitinib clinical trials using the EQ-5D. Drug and other health care costs were estimated from nationally published sources, and reported in 2008 New Israeli Shekels (NIS). Treatment effectiveness was measured in QALYs gained. Costs and benefi ts were discounted annually at 3%. We used a series of univariate and probabilistic sensitivity analyses to test the robustness of our base-case fi ndings. RESULTS: Sunitinib was the most effective intervention and resulted in a gain of 0.27 QALYs compared with Sorafenib and 0.08 QALYs gained compared with Bevacizumab/ INF-alpha or Temsirolimus. The total discounted drug cost for treating mRCC patients was 277,184 NIS for Sorafenib, 380,749 NIS for Temsirolimus, 343,712 NIS for Sunitinib, and 420,987 NIS for Bevacizumab/INF-alpha. Treating patients with Sunitinib resulted in an ICER of 245,869 NIS ( $60,000) per QALY gained when compared with Sorafenib, and was the dominant intervention compared to the other treatment modalities. The model results were robust to changes in a wide range of model parameters, including treatment effi cacy and follow-up treatment costs. CONCLUSIONS: Our model indicates that Sunitinib is a cost-saving alternative, when compared with Bevacizumab/INFalpha, and Temsirolimus and is within the accepted threshold for cost-effective interventions when compared with Sorafenib.
PCN33 COST-EFFECTIVENESS ANALYSIS OF SORAFENIB ASSOCIATED TO BEST SUPPORTIVE CARE (BSC) VERSUS BEST SUPPORTIVE CARE ALONE IN THE SECOND LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
Teich V 1 , Fernandes RA 1 , Schiola A 2 1 MedInsight, Rio de Janeiro, Brazil, 2 Bayer Schering Pharma Brazil, São Paulo, Brazil OBJECTIVES: The objective of the study was to develop a cost-effectiveness analysis of sorafenib associated to BSC versus BSC alone in the second line treatment of advanced renal cell carcinoma (RCC) under the Brazilian public health care system perspective. METHODS: A Markov model was developed to project the lifetime costs and outcomes associated with the disease progression of patients receiving sorafenib/ BSC or BSC alone. The cycle duration was three months and the corresponding transition probabilities were obtained from the TARGET study. The model considered three health states: progression free survival, disease progression and death. The outcomes were expressed as life years gained. Only direct medical costs were considered in the analysis, including drugs, physician visits, monitoring and treatment of adverse events. Unit costs for drugs were obtained from the Brazilian Health Prices Database (BPS) and procedure costs were extracted from the National Database of Ambulatory Costs (SIA/DATASUS). Costs and outcomes were discounted at an annual 5% discount rate. Main parameters were evaluated in a sensitivity analysis. RESULTS: In a lifetime horizon, total costs per patient were R$48,285 for sorafenib/BSC and R$7,356 for BSC alone. Mean progression free survival for patients treated with both alternatives were 2066 years and 1243 years, respectively, resulting in an incremental cost-effectiveness ratio of R$49,751 (US$21,553) per life year gained. Varying the time horizon of the analysis increased the ICER for values above R$70,000 in time horizons below 5 years. Varying the discount rate between 0% and 10% led to ICERs between R$46.589 and R$61,302, respectively. CONCLUSIONS: There's no defi ned threshold for the accepted ICER in Brazil. Considering international standards, the incremental cost-effectiveness ratio would be around 3 times the Brazilian per capita Gross Domestic Product. Therefore, sorafenib/BSC appears to be cost-effective in the management of advanced RCC. To analyze the cost-effectiveness of temozolomide in the treatment of newly diagnosed glioblastoma multiforme versus radiotherapy alone from the Mexican health care perspective. METHODS: A cost-effectiveness analysis was performed based on a Markov model, with three health states: initial, disease progression and death. This model allowed us to compare the expected outcomes and costs associated with temozolomide compared with radiotherapy alone for a synthetic cohort of patients aged 55 years over a 5-year period. The model cycles every six months and continues until all patients die. The probabilities of transition between health states were obtained from the literature. Costs were expressed in 2008 US dollar. Outcome estimates included the incremental cost-effectiveness ratio (ICER) and cost per life-year (LY) gained. Costs and health outcomes were discounted at 5%. Second-order Monte Carlo simulations were undertaken in which values were randomly drawn from distributions of these parameters. RESULTS: The accumulated discounted effect is 1.03 LY per patient receiving temozolomide compared to 0.93 LY for radiotherapy alone. Total lifetime medical cost was US$31,698 for temozolomide vs US$30,715 for radiotherapy alone. The incremental cost-effectiveness of temozolomide was US$983 per life year gained. There is a 70% probability that temozolomide is cost-effective at a US$10,000 per life-year saved threshold and a slightly more than 95% probability of being cost-effective at a US$18,000 per life-year saved threshold. CONCLUSIONS: Results from these analyses suggest that in the Mexican setting, use of temozolomide in place of radiotherapy alone for treatment of glioblastoma multiforme is likely to be cost saving. These conclusions are supported by the use of conservative assumptions and sensitivity analyses.
PCN34 ECONOMIC EVALUATION OF TEMOZOLOMIDE FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN MEXICO

